Elecoglipron: The Science Behind the Once-Daily Oral GLP-1 Obesity Pill
The Lancet just published the Phase IIb results for elecoglipron, AstraZeneca's once-daily oral GLP-1 receptor agonist. Alex Keane analyzes the VISTA and SOLSTICE clinical data, the science of oral small molecules, and what this means for the future of obesity and diabetes care.
June 26, 20268 min read
Read Article ›